Clozapine is the most effective antipsychotic ever discovered. In treatment-resistant schizophrenia — patients who have failed at least two adequate prior antipsychotic trials — clozapine works when nothing else does. It is also the only antipsychotic with demonstrated efficacy in reducing suicide in schizophrenia. No other agent in this class has shown that effect. By any reasonable measure of efficacy, clozapine is in a category of its own.
- Class
- Second-generation antipsychotic (atypical)
- Mechanism
- Very broad receptor profile: weak D2 antagonism + strong 5-HT2A + H1 + M1 + alpha-1 + 5-HT2C + others. The "dirtiest" antipsychotic — and uniquely effective in treatment-resistant schizophrenia.
- Typical dose
- Start 12.5-25 mg, titrate carefully to 300-600 mg/day (sometimes higher)
- Half-life
- ~12 hours
- FDA indications
- Treatment-resistant schizophrenia (after 2 failed antipsychotic trials); reduction of recurrent suicidal behavior in schizophrenia/schizoaffective disorder
- Key adverse effects
- Agranulocytosis (1-2%), neutropenia, severe sedation, weight gain, sialorrhea (hypersalivation), constipation (severe, can be fatal), seizure (dose-dependent), myocarditis (early), orthostasis, anticholinergic effects, metabolic syndrome
Black box: Severe neutropenia — ANC monitoring (weekly for 6 months, every 2 weeks for 6 months, then monthly); the Clozapine REMS program was eliminated by the FDA in June 2025, so this monitoring is now per labeling, not REMS-mandated. Also orthostatic hypotension and seizures; myocarditis and cardiomyopathy; increased mortality in elderly with dementia-related psychosis
Most effective antipsychotic in treatment-resistant schizophrenia — and uniquely reduces suicide. REMS requires regular CBC monitoring (weekly first 6 months, biweekly second 6 months, monthly after). Constipation can be lethal (paralytic ileus) — aggressive bowel regimen mandatory. Despite burden, clozapine is underprescribed — represents one of the most consequential underuse problems in psychiatry.
It is also one of the most demanding medications in psychiatry. The mandatory REMS blood monitoring — weekly CBC for the first six months, biweekly for the next six, monthly thereafter — is required because of the risk of severe neutropenia and agranulocytosis. ANC thresholds determine continuation, hold, or discontinuation: above 1500, continue; 1000-1499, continue with extra monitoring; 500-999, interrupt; below 500, discontinue. The infrastructure is non-negotiable.
The receptor profile is the broadest of any antipsychotic: weak D2 antagonism (much weaker than most), strong 5-HT2A antagonism, plus H1, M1, alpha-1, 5-HT2C, 5-HT6, and others. The "dirtiness" is what makes clozapine effective in treatment-resistant cases — and what produces a broad side effect profile.
Clozapine is the uniquely effective antipsychotic for treatment resistance — a loose, fast-dissociating D2 binder whose efficacy is matched by a serious adverse-effect burden requiring intensive monitoring.
Mechanism note: Clozapine is reserved for treatment-resistant schizophrenia because it is the only agent that works there — but its agranulocytosis, metabolic, ileus, myocarditis, and seizure risks make it the most monitoring-intensive psychotropic.
Other toxicities are substantial. Severe sedation. Substantial weight gain (5-15+ percent body weight). Significant metabolic effects. Sialorrhea (hypersalivation, often distressing). Constipation — sometimes severe, occasionally causing paralytic ileus, sometimes fatal. Aggressive bowel regimen is mandatory. Seizure threshold lowering — dose-dependent, with prophylactic anticonvulsant sometimes added at high doses. Myocarditis — usually early in treatment, requires baseline troponin and CRP plus monitoring. Orthostasis.
Initiation is slow. Start 12.5-25 mg, titrate over weeks to target doses of 300-600 mg per day, sometimes higher. The titration is gradual to mitigate sedation, orthostasis, and seizure risk. The patient is often on the drug for months before optimal effect emerges.
- Cost
- Generic: ~$30-80/month. Drug itself is cheap.
- Generic status
- Generic for decades.
- Formulary typical
- Generic Tier 1-2.
- Access friction
- REMS is the central friction. Mandatory weekly CBC weeks 1-26, biweekly weeks 27-52, monthly thereafter. ANC entered into Clozapine REMS portal before each dispense. Patient cannot skip blood draws; pharmacy cannot dispense without ANC. Substantial infrastructure for prescriber and patient.
Prescriber tip: Before initiating, confirm: lab access for weekly CBC, REMS portal account, pharmacy familiar with REMS workflow, patient committed to the monitoring schedule. Substantially underprescribed for treatment-resistant schizophrenia despite uniqueness; build the infrastructure and the work becomes routine.
Despite all this, clozapine is one of the most consequentially underprescribed medications in psychiatry. Patients with treatment-resistant schizophrenia who could benefit often do not receive it, partly because of the monitoring infrastructure and partly because of clinician unfamiliarity. The patient who has failed two adequate prior antipsychotics meets criteria for clozapine — and deserves at least a discussion of it.
For the patient with treatment-resistant schizophrenia, clozapine is what we have. Use it well or refer to someone who will.